SOM Biotech to participate at the BIO-Europe Spring

posted on March 1, 2021
Bio-Europe Spring 2021
SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22nd – 25th, which will take place digitally due to the pandemic situation. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma and biotech sectors but also…
continue reading →

Rare Disease Day 2021

posted on February 24, 2021
On the 28th of February, we'll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!! We encourage everyone to support Rare Disease Day in…
continue reading →

SOM Biotech at Chiba Healthcare Business Forum 2021

posted on February 1, 2021
SOM Biotech ends 2020 with an advanced and robust pipeline
SOM Biotech ends 2020 with an advanced and robust pipeline
SOM Biotech will attend the “Chiba Global Healthcare Business Forum 2021” on February 3rd – 4th, which will take place digitally due to the pandemic situation. Organized by the Japanese External Trade Association, the Chiba Healthcare Business Forum attracts the most advanced academic and research institutions as well as healthcare and life science companies worldwide…
continue reading →

HAPPY END OF THE 2020!

posted on December 21, 2020
We wish a happy and healthy holiday to everyone who has trusted SOM Biotech during this challenging year marked by the Covid-19 pandemic. Thank you, especially to the entire team, whose hard work has been essential in such a demanding year. We wish you a safe and Merry Christmas and a happy and prosperous 2021.
continue reading →

SOM Biotech ends 2020 with an advanced and robust pipeline that strengthens the company’s future

posted on December 21, 2020
SOM Biotech ends a notable year 2020
SOM Biotech ends the notable year 2020 with relevant advances in its pipeline. The company started 2020 with positive results from the Phase 2a proof-of-concept to evaluate the safety and efficacy of SOM3355, an inhibitor of the Vesicular Monoamine Transporter-2 (VMAT2), in Huntington´s disease (HD) patients with chorea. The clinical efficacy of SOM3355 in reducing…
continue reading →

SOM Biotech at the BIO- Partnering JPM Virtual Event 2021

posted on December 18, 2020
SOM Biotech announces its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11th - 15th. The conference, a leading virtual partnering and business development initiative for the biotechnology industry organized by Biotechnology Innovation Organization, provides a One-on-One partnering platform to give companies access to potential strategic partners and…
continue reading →